Lipocine Inc. Files 8-K on Shareholder Votes and Financials
Ticker: LPCN · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-actions, financials, disclosure
Related Tickers: LPCN
TL;DR
LPCN filed an 8-K, shareholders voting on stuff, financials updated.
AI Summary
Lipocine Inc. filed an 8-K on June 5, 2024, reporting on the submission of matters to a vote of security holders and financial statements. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Salt Lake City, Utah.
Why It Matters
This filing indicates that Lipocine Inc. is proceeding with important corporate actions requiring shareholder approval and is providing updated financial information.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- June 5, 2024 (date) — Date of Earliest Event Reported
- 675 Arapeen Drive, Suite 202 (location) — Principal Executive Offices Address
- Salt Lake City, Utah (location) — Principal Executive Offices City and State
- 84108 (location) — Principal Executive Offices Zip Code
- 001-36357 (identifier) — Commission File Number
- 99-0370688 (identifier) — IRS Employer Identification Number
FAQ
What specific matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.
What is the primary business of Lipocine Inc.?
Lipocine Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 5, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
Has the company changed its name or address recently?
The filing indicates 'Not Appli' for former company name or address changes since the last report.
Filing Stats: 786 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-06-05 16:32:30
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 64KB
- form8-k_001.jpg (GRAPHIC) — 6KB
- 0001493152-24-022767.txt ( ) — 251KB
- lpcn-20240605.xsd (EX-101.SCH) — 3KB
- lpcn-20240605_lab.xml (EX-101.LAB) — 33KB
- lpcn-20240605_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: June 5, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer